Industry Supported Session Programme

Alberico L. Catapano was born in Milano in 1952. Received degree from the University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dislypidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response. Alberico Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

Alberico L. Catapano was born in Milano in 1952. Received degree from the University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dislypidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response. Alberico Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012). He is a President of Polish Mother’s Memorial Hospital – Research Institute (PMMHRI) (February 2014-), Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Hypertension (2008-) at the Medical University of Lodz and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University Hospital in Lodz, Poland (2009-).

He is member of the Executive Committee of European Atherosclerosis Society (EAS) working as an Advisor in Matters related to European Union Relations/Contacts, and the International Atherosclerosis Society (IAS) Regional Federation Executive Committee Member for Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) – the official partner of National Lipid Association (NLA, US) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP) (2015-), which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is a member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania (2014-). 

Prof. Banach has published over 750 original articles, reviews, editorials and book chapters in the field of hypertension, dyslipidemia, cardiology, cardiac surgery, and risk stratification (622 acc. to PubMed, 706 acc. to Web of Knowledge/Publons, 553 acc. to SCOPUS, 766 acc. to ResearchGate – RG Score: 52.19, and 1020 acc. to Google Scholar). His combined IF (for only full-text manuscripts) is over 7000 pts., number of citations: 10,055 (acc. Web of Science Core Collection), 11,026 (acc. SCOPUS), 10,651 (acc. ResearchGate), and 16,027 (acc. Google Scholar), Hirsch’s Index = 45 (WoS/Publons), 47 (SCOPUS), 48 (ResearchGate) and 58 (i10-index: 330) (Google Scholar) – being within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 22 TOP Papers). Prof. Banach is also within top 10 worldwide experts according to ExpertScape in the field of statin therapy (7), cholesterol (13), and HDL cholesterol (10).

He is a laureate of several prizes and award, including: Doctor Honoris Causa of the Institute of Cardiology in Kiev (2018), and the University of Medicine and Pharmacy Victor Babes in Timisoara (2017); Gold Honorary Medal for scientific achievements of the Medical Faculty of Medical University in Kosice, Slovak Republic (2018), The Manager of the Year 2016 – Public Entities (2017), “Gold Scalpel” Distinction in 2016 for the Innovation; The Personality of the Year 2013 in Poland for the development of science in the field of healthcare – founded by the Heath Manager journal (Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), 18 individual and group scientific awards of President of Medical University of Lodz (2009-2016); START Award (2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007) and Heart Failure Association of ESC (2005, 2007).

His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension, new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy, prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare diseases), dyslipidemia therapy (statins, new drugs, combined treatment) and new drugs in CVD therapy.

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012). He is a President of Polish Mother’s Memorial Hospital – Research Institute (PMMHRI) (February 2014-), Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Foreign Affairs Office (2012-2014), Head of Department of Hypertension (2008-) at the Medical University of Lodz and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at the WAM University Hospital in Lodz, Poland (2009-).

He is member of the Executive Committee of European Atherosclerosis Society (EAS) working as an Advisor in Matters related to European Union Relations/Contacts, and the International Atherosclerosis Society (IAS) Regional Federation Executive Committee Member for Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) – the official partner of National Lipid Association (NLA, US) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the International Lipid Expert Panel (ILEP) (2015-), which has been founded to prepare recommendations in the area of preventive cardiology in the most debatable issues that have not been covered in the existing guidelines. He is a member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania (2014-). 

Prof. Banach has published over 750 original articles, reviews, editorials and book chapters in the field of hypertension, dyslipidemia, cardiology, cardiac surgery, and risk stratification (622 acc. to PubMed, 706 acc. to Web of Knowledge/Publons, 553 acc. to SCOPUS, 766 acc. to ResearchGate – RG Score: 52.19, and 1020 acc. to Google Scholar). His combined IF (for only full-text manuscripts) is over 7000 pts., number of citations: 10,055 (acc. Web of Science Core Collection), 11,026 (acc. SCOPUS), 10,651 (acc. ResearchGate), and 16,027 (acc. Google Scholar), Hirsch’s Index = 45 (WoS/Publons), 47 (SCOPUS), 48 (ResearchGate) and 58 (i10-index: 330) (Google Scholar) – being within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 22 TOP Papers). Prof. Banach is also within top 10 worldwide experts according to ExpertScape in the field of statin therapy (7), cholesterol (13), and HDL cholesterol (10).

He is a laureate of several prizes and award, including: Doctor Honoris Causa of the Institute of Cardiology in Kiev (2018), and the University of Medicine and Pharmacy Victor Babes in Timisoara (2017); Gold Honorary Medal for scientific achievements of the Medical Faculty of Medical University in Kosice, Slovak Republic (2018), The Manager of the Year 2016 – Public Entities (2017), “Gold Scalpel” Distinction in 2016 for the Innovation; The Personality of the Year 2013 in Poland for the development of science in the field of healthcare – founded by the Heath Manager journal (Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), 18 individual and group scientific awards of President of Medical University of Lodz (2009-2016); START Award (2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007) and Heart Failure Association of ESC (2005, 2007).

His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension, new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy, prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare diseases), dyslipidemia therapy (statins, new drugs, combined treatment) and new drugs in CVD therapy.

Kausik Kumar Ray is currently Professor of Public Heath, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 59, an i10 of 123 and over 26,000 citations overall, including over 170 publications in journals including NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 68 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Alberico L. Catapano was born in Milano in 1952. Received degree from the University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dislypidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response. Alberico Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

S. Lale Tokgözoğlu, M.D., F.A.C.C., F.E.S.C. was born in 1959 in Ankara, Turkey. She graduated from the Hacettepe University Faculty of Medicine in 1982 on the honor roll. After finishing the Internal Medicine Residency program in the Hacettepe University Faculty of Medicine Department of Internal Medicine on 1988, she completed a fellowship program on Cardiology and Atherosclerosis at the Baylor College of Medicine in Houston, Texas. Dr. Tokgözoğlu returned to the Hacettepe University in 1991 to become Associate Professor of Cardiology, and later Professor of Cardiology in 1998.

Prof. Tokgözoğlu has served on the Executive Committee of the European Society of Atherosclerosis as member between 2003 and 2005, as Secretary between 2005-2009, as Vice President of the European Atherosclerosis Society between 2009-2013 and as President since January 2017. She was the President of the 77th European Atherosclerosis Society meeting in Istanbul. She also served as the President of the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. She has served for 2 years on board of the European Society of Cardiology Fellowship and Training Committee and for 2 years on the board of the Education Committee. She has also served first as Member-at-Large (Europe) of the Executive Committee of the International Society of Atherosclerosis, then as President of the European Federation of the International Atherosclerosis Society followed by the post of Secretary of the International Society of Atherosclerosis.

Prof. Tokgözoğlu has served on the Board of the Prevention Association of the European Society of Cardiology chairing their Education Committee. She has been a member of the Young Investigator Award Committees of the International Atherosclerosis Society in Stockholm 2000, European Atherosclerosis Society in Prague in 2005 and has served in the Scientific Program Committe of the European Society of Cardiology in 2009, 2010, 2015, 2016, 2017 and 2018.

Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014.

Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and as Vice President between 2008 and 2010 and the President of the Turkish Society of Cardiology between 2014-2016. She was the first female President of this society in its history of 52 years. She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey. She has been on the Guideline Committee for the Prevention of Coronary Heart Disease in Turkey in 1995 and in 2002 when the Guidelines were revised.She has also been an author on the EAS/ESC dyslipidemia guideines in 2011. She also received the Paul Dudley White International Science Team Award in 2017.

Prof. Tokgözoğlu is currently a Fellow of the American College of Cardiology and European Society of Cardiology. She is also member of many societies of her specialty. She has won the “Prof. Dr. Şeref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994 and second runner up in the Pfizer Cardiology Scientific Award in 1999. She also received the Paul Dudley White International Science Team Award in 2017.

Kausik Kumar Ray is currently Professor of Public Heath, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 59, an i10 of 123 and over 26,000 citations overall, including over 170 publications in journals including NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 68 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Erik Stroes is Professor and Chair of the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands. Professor Stroes received his medical degree from the University of Rotterdam in 1991, and subsequently trained in internal medicine at the University Medical Center of Utrecht. His major research interest over the last two decades has been the role of the vessel wall in atherogenesis, especially the contributions of lipid disorders and inflammation. Recent research has focused on targeting epigenetic changes in innate immune cells in atherosclerosis that may offer future potential for imaging, biomarkers and therapies. Professor Stroes is a member of the Council for Basic Science, the American Heart Association, the International Atherosclerosis Society and Chair of the Dutch Society of Atherosclerosis. He has authored more than 300 scientific publications associated with his research interests.

Erik Stroes is Professor and Chair of the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands. Professor Stroes received his medical degree from the University of Rotterdam in 1991, and subsequently trained in internal medicine at the University Medical Center of Utrecht. His major research interest over the last two decades has been the role of the vessel wall in atherogenesis, especially the contributions of lipid disorders and inflammation. Recent research has focused on targeting epigenetic changes in innate immune cells in atherosclerosis that may offer future potential for imaging, biomarkers and therapies. Professor Stroes is a member of the Council for Basic Science, the American Heart Association, the International Atherosclerosis Society and Chair of the Dutch Society of Atherosclerosis. He has authored more than 300 scientific publications associated with his research interests.

Kausik Kumar Ray is currently Professor of Public Heath, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials within the Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society also serving on the EAS Consensus panel. Professor Ray has been the national lead investigator (SC or EC member) for several major medical trials, and is currently involved in 8 ongoing trials in lipids and diabetes and the PI for ORION 1 assessing PCSK9 inhibition through RNA interference and BETONMACE assessing BET protein inhibition in patients with ACS. Professor Ray’s research interests have focused on the prevention of coronary disease with a focus on lipids, diabetes, biomarkers and risk prediction. He has an H index of 59, an i10 of 123 and over 26,000 citations overall, including over 170 publications in journals including NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. Key original contributions which have influenced European and American guidelines include demonstrating the early benefits of statin therapy post ACS, the impact of more/less intensive glycaemic control on CVD and the risks/benefits of aspirin therapy in primary prevention. Recently, his work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. Currently Professor Ray leads the EAS FH Studies collaboration which is the first global registry of FH and includes 68 countries, as well as being the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.

Alberico L. Catapano was born in Milano in 1952. Received degree from the University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dislypidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response. Alberico Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

Alberico L. Catapano was born in Milano in 1952. Received degree from the University of Milano in 1975 and a specialization in Clinical Pharmacology in 1979. From 1972 been involved in the field of Atherosclerosis, Lipids, Lipoproteins and genetic dislypidaemias. From the scientific standpoint Prof. Catapano has made landmark observations regarding the role of HSP’s and of Petranxins in Atherogenesis and on the role of HDL in the modulation of the immune response. Alberico Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).

Professor Catapano is Past President of the European Atherosclerosis Society (EAS), the Chairman of EAS Educational, Guidelines & Corporate Activities Committees and the Chairman of the EAS/ESC guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.

He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.

M. John Chapman is Research Professor at the University of Pierre and Marie Curie, and Director Emeritus of the National Institute for Health and Medical Research (INSERM), Pitié-Salpétrière University Hospital, Paris, France. Together with Professor Henry Ginsberg (University of Columbia, New York, USA) he has led the EAS Consensus Panel initiative (for full details of the Consensus Panel papers see https://www.eas-society.org/page/consensus_papers ). Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, and the Gladstone Foundation for Cardiovascular Disease, San Francisco, USA. He is the recipient of the 2014 European Lipid Science Award and the 2015 Antonio M. Gotto Jr Prize for Atherosclerosis Research from the International Atherosclerosis Society. Present research interests include the relationship of the lipidome and proteome to the functionality of high-density lipoprotein (HDL) particles in health and cardiometabolic disease, and on the development of new anti-atherosclerotic therapeutics targeted to HDL.

M. John Chapman is Research Professor at the University of Pierre and Marie Curie, and Director Emeritus of the National Institute for Health and Medical Research (INSERM), Pitié-Salpétrière University Hospital, Paris, France. Together with Professor Henry Ginsberg (University of Columbia, New York, USA) he has led the EAS Consensus Panel initiative (for full details of the Consensus Panel papers see https://www.eas-society.org/page/consensus_papers ). Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, and the Gladstone Foundation for Cardiovascular Disease, San Francisco, USA. He is the recipient of the 2014 European Lipid Science Award and the 2015 Antonio M. Gotto Jr Prize for Atherosclerosis Research from the International Atherosclerosis Society. Present research interests include the relationship of the lipidome and proteome to the functionality of high-density lipoprotein (HDL) particles in health and cardiometabolic disease, and on the development of new anti-atherosclerotic therapeutics targeted to HDL.

M. John Chapman is Research Professor at the University of Pierre and Marie Curie, and Director Emeritus of the National Institute for Health and Medical Research (INSERM), Pitié-Salpétrière University Hospital, Paris, France. Together with Professor Henry Ginsberg (University of Columbia, New York, USA) he has led the EAS Consensus Panel initiative (for full details of the Consensus Panel papers see https://www.eas-society.org/page/consensus_papers ). Professor Chapman undertook his undergraduate studies at Aberdeen University and the Middlesex Hospital Medical School, University of London. He subsequently trained in cardiovascular lipidology at the Cardiovascular Research Institute of the University of California Medical Center, and the Gladstone Foundation for Cardiovascular Disease, San Francisco, USA. He is the recipient of the 2014 European Lipid Science Award and the 2015 Antonio M. Gotto Jr Prize for Atherosclerosis Research from the International Atherosclerosis Society. Present research interests include the relationship of the lipidome and proteome to the functionality of high-density lipoprotein (HDL) particles in health and cardiometabolic disease, and on the development of new anti-atherosclerotic therapeutics targeted to HDL.